These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28583138)

  • 1. Molecular characterization of breast cancer cell lines through multiple omic approaches.
    Smith SE; Mellor P; Ward AK; Kendall S; McDonald M; Vizeacoumar FS; Vizeacoumar FJ; Napper S; Anderson DH
    Breast Cancer Res; 2017 Jun; 19(1):65. PubMed ID: 28583138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.
    Bancovik J; Moreira DF; Carrasco D; Yao J; Porter D; Moura R; Camargo A; Fontes-Oliveira CC; Malpartida MG; Carambula S; Vannier E; Strauss BE; Wakamatsu A; Alves VA; Logullo AF; Soares FA; Polyak K; Belizário JE
    BMC Cancer; 2015 Feb; 15():70. PubMed ID: 25879571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer.
    Elbaz M; Ahirwar D; Ravi J; Nasser MW; Ganju RK
    Oncotarget; 2017 May; 8(18):29668-29678. PubMed ID: 27213582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
    Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures.
    Drews-Elger K; Brinkman JA; Miller P; Shah SH; Harrell JC; da Silva TG; Ao Z; Schlater A; Azzam DJ; Diehl K; Thomas D; Slingerland JM; Perou CM; Lippman ME; El-Ashry D
    Breast Cancer Res Treat; 2014 Apr; 144(3):503-17. PubMed ID: 24567196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic pathways modulated by Twist in breast cancer.
    Vesuna F; Bergman Y; Raman V
    BMC Cancer; 2017 Jan; 17(1):52. PubMed ID: 28086829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray.
    Akkiprik M; Nicorici D; Cogdell D; Jia YJ; Hategan A; Tabus I; Yli-Harja O; Y D; Sahin A; Zhang W
    Technol Cancer Res Treat; 2006 Dec; 5(6):543-51. PubMed ID: 17121430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells.
    Chung ST; Geerts D; Roseman K; Renaud A; Connelly L
    Mol Cancer; 2017 Feb; 16(1):27. PubMed ID: 28143606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Saunus JM; Smart CE; Kutasovic JR; Johnston RL; Kalita-de Croft P; Miranda M; Rozali EN; Vargas AC; Reid LE; Lorsy E; Cocciardi S; Seidens T; McCart Reed AE; Dalley AJ; Wockner LF; Johnson J; Sarkar D; Askarian-Amiri ME; Simpson PT; Khanna KK; Chenevix-Trench G; Al-Ejeh F; Lakhani SR
    Breast Cancer Res Treat; 2018 Jan; 167(1):289-301. PubMed ID: 28889351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development.
    Czerwińska P; Shah PK; Tomczak K; Klimczak M; Mazurek S; Sozańska B; Biecek P; Korski K; Filas V; Mackiewicz A; Andersen JN; Wiznerowicz M
    Oncotarget; 2017 Jan; 8(1):863-882. PubMed ID: 27845900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
    Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
    Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coupling proteomics and transcriptomics in the quest of subtype-specific proteins in breast cancer.
    Pavlou MP; Dimitromanolakis A; Diamandis EP
    Proteomics; 2013 Apr; 13(7):1083-95. PubMed ID: 23386393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
    Baumann J; Wong J; Sun Y; Conklin DS
    BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.